(Q43175985)

English

American Association of Pharmaceutical Scientists National Biotechnology Conference Short Course: Translational Challenges in Developing Antibody-Drug Conjugates: May 24, 2012, San Diego, CA.

scientific article published on 19 December 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

15 November 2017

American Association of Pharmaceutical Scientists National Biotechnology Conference Short Course: Translational Challenges in Developing Antibody-Drug Conjugates: May 24, 2012, San Diego, CA. (English)

1 reference

Europe PubMed Central

PMC publication ID

15 November 2017

0 references

object named as

Bernd Meibohm

6

0 references

author name string

Karen Thudium

1

1 reference

Europe PubMed Central

PMC publication ID

15 November 2017

Sanela Bilic

2

1 reference

Europe PubMed Central

PMC publication ID

15 November 2017

Douglas Leipold

3

1 reference

Europe PubMed Central

PMC publication ID

15 November 2017

William Mallet

4

1 reference

Europe PubMed Central

PMC publication ID

15 November 2017

Surinder Kaur

5

1 reference

Europe PubMed Central

PMC publication ID

15 November 2017

Hans Erickson

7

1 reference

Europe PubMed Central

PMC publication ID

15 November 2017

Jay Tibbitts

8

1 reference

Europe PubMed Central

PMC publication ID

15 November 2017

Hong Zhao

9

1 reference

Europe PubMed Central

PMC publication ID

15 November 2017

Manish Gupta

10

1 reference

Europe PubMed Central

PMC publication ID

15 November 2017

publication date

19 December 2012

1 reference

Europe PubMed Central

PMC publication ID

15 November 2017

Monoclonal Antibodies

1 reference

Europe PubMed Central

PMC publication ID

15 November 2017

5

1 reference

Europe PubMed Central

PMC publication ID

15 November 2017

1

1 reference

Europe PubMed Central

PMC publication ID

15 November 2017

5-12

1 reference

Europe PubMed Central

PMC publication ID

15 November 2017

Semi-mechanistic population pharmacokinetic model of multivalent trastuzumab emtansine in patients with metastatic breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3564886

25 May 2018

A population pharmacokinetic/pharmacodynamic model of thrombocytopenia characterizing the effect of trastuzumab emtansine (T-DM1) on platelet counts in patients with HER2-positive metastatic breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3564886

25 May 2018

Pharmacokinetic considerations for antibody drug conjugates

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3564886

25 May 2018

High-content live-cell imaging assay used to establish mechanism of trastuzumab emtansine (T-DM1)--mediated inhibition of platelet production

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3564886

25 May 2018

Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody-drug conjugate in development for the treatment of HER2-positive cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3564886

25 May 2018

Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3564886

25 May 2018

Projecting human pharmacokinetics of therapeutic antibodies from nonclinical data: what have we learned?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3564886

25 May 2018

Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3564886

25 May 2018

Catabolic fate and pharmacokinetic characterization of trastuzumab emtansine (T-DM1): an emphasis on preclinical and clinical catabolism.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3564886

15 August 2018

Drug interaction potential of trastuzumab emtansine (T-DM1) combined with pertuzumab in patients with HER2-positive metastatic breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3564886

15 August 2018

Identifiers

10.4161/MABS.22909

1 reference

Europe PubMed Central

PMC publication ID

15 November 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

15 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

15 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43175985&oldid=1600936747"